RxDoctor Payments Data

Stephen Hantus, MD

Neurology · Cleveland, OHNPI 1740459510

Payments from drug & device makers

$136,411in general payments, 2019–2025

Across 57 payments — averaging $2393.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$76K
  • Immedica Pharma US, Inc.$52K
  • Eisai Inc.$6K
  • UCB, Inc.$1K
  • SK Life Science, Inc.$364
  • Jazz Pharmaceuticals Inc.$255
  • plus $605 from 6 others

What the payments were for

  • Consulting fees$5,74059%
  • Travel & lodging$1,02710%
  • Food & beverage$3,04031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,411 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$242,307
Medicare patients
847
Services billed
1,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam58$105,506
FycompaPerampanel56$77,060
NayzilamMidazolam26$29,369
Lacosamide134$18,352
XcopriCenobamate11$15,952
Clobazam120$11,815
Zonisamide235$10,887
Lamotrigine ErLamotrigine34$10,505
Levetiracetam ErLevetiracetam33$5,393
DepakoteDivalproex Sodium11$4,860
Oxcarbazepine54$4,362
Divalproex Sodium ErDivalproex Sodium38$3,845
Carbamazepine ErCarbamazepine19$3,701
Levetiracetam80$2,723
Lamotrigine121$2,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$1,451$134,87584 claims
Eisai Inc.Fycompa$6,232$77,06056 claims
SK Life Science, Inc.Xcopri$364$15,95211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →